Lifeward (NASDAQ:LFWD) Releases Earnings Results, Misses Estimates By $3.53 EPS

Lifeward (NASDAQ:LFWD) issued its earnings results on Wednesday. The company reported ($3.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($3.53), reports. The company had revenue of $5.08 million for the quarter, compared to analysts’ expectations of $7.87 million. Lifeward had a negative net margin of 121.82% and a negative return on equity of 183.18%.

Here are the key takeaways from Lifeward’s conference call:

• The strategic agreement with Oramed was approved and is pending close; Lifeward has already received a $3.0M loan and expects a $10M convertible note plus additional financing at close, materially strengthening its liquidity to support growth initiatives.
• Lifeward gains exposure to Oramed’s clinical-stage oral insulin ORMD-0801, which management says may reduce hypoglycemia and weight gain versus injectable insulin, and will advance a new U.S. study under a funding structure that preserves Lifeward’s operational focus.
• Lifeward acquired Skelable IP and the core engineering team to develop a powered upper-extremity exoskeleton, targeting a commercial launch in about 18–24 months with a likely low regulatory barrier (management expects 510(k)-exempt status) and a large stroke survivor addressable market.
• Full‑year revenue fell ~14% to $22.0M (AlterG down 18%, MyoCycle down 50%), year-end unrestricted cash was only $2.2M, and the company continued to record operating losses and significant cash burn, leaving it dependent on the Oramed financing to stabilize liquidity.
• Management restructured to a hybrid direct-plus-channel commercial model and expanded payer engagement, achieving Medicare Advantage coverage with Aetna, Humana and UnitedHealthcare (covering >16 million lives) and broader international distribution, which they expect will drive unit growth and backlog conversion.

Lifeward Trading Down 2.6%

LFWD stock traded down $0.17 during mid-day trading on Thursday, reaching $6.55. The company’s stock had a trading volume of 2,424 shares, compared to its average volume of 28,063. The company’s 50 day moving average is $6.93 and its two-hundred day moving average is $7.41. Lifeward has a fifty-two week low of $4.14 and a fifty-two week high of $23.04. The stock has a market cap of $9.95 million, a PE ratio of -0.18 and a beta of 0.12.

Institutional Investors Weigh In On Lifeward

Large investors have recently made changes to their positions in the stock. Virtu Financial LLC lifted its position in shares of Lifeward by 158.0% during the fourth quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock worth $35,000 after purchasing an additional 37,037 shares in the last quarter. Jane Street Group LLC boosted its stake in Lifeward by 77.3% during the 4th quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock worth $40,000 after purchasing an additional 29,927 shares during the period. HRT Financial LP grew its stake in shares of Lifeward by 149.7% in the 4th quarter. HRT Financial LP now owns 49,081 shares of the company’s stock valued at $28,000 after purchasing an additional 29,423 shares during the last quarter. Finally, Citadel Advisors LLC boosted its holdings in shares of Lifeward by 1,271.8% in the third quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock valued at $152,000 after acquiring an additional 198,406 shares in the last quarter. 26.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have commented on LFWD. HC Wainwright increased their price target on Lifeward to $10.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lifeward in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $10.00.

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.